TD Waterhouse Canada Inc. Buys 13,205 Shares of Illumina, Inc. $ILMN

TD Waterhouse Canada Inc. lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 263.6% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 18,215 shares of the life sciences company’s stock after purchasing an additional 13,205 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Illumina were worth $3,349,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ILMN. Fiduciary Financial Advisors bought a new stake in Illumina during the 2nd quarter worth $26,000. Keating Financial Advisory Services Inc. bought a new position in Illumina in the second quarter valued at about $32,000. Rakuten Securities Inc. bought a new position in Illumina in the second quarter valued at about $33,000. Elyxium Wealth LLC acquired a new stake in shares of Illumina during the fourth quarter valued at about $25,000. Finally, Elevation Wealth Partners LLC boosted its stake in shares of Illumina by 52.5% during the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ILMN. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research note on Thursday, May 14th. Stifel Nicolaus lifted their target price on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Finally, Evercore restated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $191.31.

Insider Activity

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the transaction, the director owned 770,350 shares in the company, valued at $168,244,440. The trade was a 13.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 2,062,465 shares of company stock worth $436,589,802. 2.90% of the stock is owned by corporate insiders.

Illumina Stock Performance

ILMN opened at $218.22 on Tuesday. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a fifty day moving average of $199.16 and a 200-day moving average of $160.04. The stock has a market cap of $32.95 billion, a PE ratio of 40.71, a price-to-earnings-growth ratio of 3.09 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.